Liquidia Technologies Inc (LQDA)vsMerck & Company Inc (MRK)
LQDA
Liquidia Technologies Inc
$75.49
-1.10%
HEALTHCARE · Cap: $6.33B
MRK
Merck & Company Inc
$120.60
+0.84%
HEALTHCARE · Cap: $283.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 22731% more annual revenue ($65.77B vs $288.06M). MRK leads profitability with a 13.6% profit margin vs 7.7%. MRK trades at a lower P/E of 32.4x. LQDA earns a higher WallStSmart Score of 54/100 (C-).
LQDA
Buy54
out of 100
Grade: C-
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LQDA.
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$120.60
$39.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 46.3%
Revenue surging 4159.0% year-over-year
Every $100 of equity generates 28 in profit
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
7.7% margin — thin
Elevated debt levels
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LQDA
The strongest argument for LQDA centers on Operating Margin, Revenue Growth, Return on Equity. Revenue growth of 4159.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : LQDA
The primary concerns for LQDA are EPS Growth, Profit Margin, Debt/Equity. A P/E of 419.0x leaves little room for execution misses. Debt-to-equity of 1.70 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
LQDA profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
LQDA carries more volatility with a beta of 0.59 — expect wider price swings.
LQDA is growing revenue faster at 4159.0% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
LQDA scores higher overall (54/100 vs 50/100) and 4159.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?